MedNews

  • Drug Industry News
  • FDA News & Alerts
  • Health & Medical News
You are here: Home / Health & Medical News / Diabetes / Novartis’ Diabetes Drug Galvus Closer to Approval in EU

Novartis’ Diabetes Drug Galvus Closer to Approval in EU

July 20, 2007 By MedNews Leave a Comment

Novartis’ diabetes drug, Galvus, is one step closer to approval in the European Union after an EU advisory committee issued a positive opinion on the drug.

Galvus is a once-daily oral medicine for patients with type 2 diabetes. The company reports that Galvus significantly reduced blood sugar levels in people age 65 and older without the increased risk of side effects that often limits more aggressive treatment in these patients.
Galvus is awaiting FDA approval in the United States, where the agency has twice delayed approval of Galvus pending further data to show that skin lesions and kidney impairments seen in an earlier animal study have not occurred in humans.
A similar drug called Januvia is marketed by Merck, and was approved by the FDA in October 2006.
Recommendations by the European Committee for Human Medicinal Products usually lead to approval of the drug for sale in all the European Union countries, and Novartis indicated that it expects a final decision within the next 90 days.

Filed Under: Diabetes



Leave a Reply

Your email address will not be published. Required fields are marked *

Search



Tag Cloud

alcohol allergies alzheimers antibiotics breast cancer cancer Centers for Disease Control (CDC) children cholesterol dementia depression Diabetes diet drug abuse exercise fda flu food genetics geriatrics h1n1 heart heart attack heart disease high blood pressure HIV/AIDS hormone therapy hypertension lungs menopause NIH obesity pain pediatrics pregnancy prostate cancer seniors sleep smoking statistics stroke sun teens USA women's health

Recent Comments

  • Mia Fritz on Health Benefits of Dark Chocolate
  • Shilpa on Why Too Much Iron Can Be Dangerous
  • Racheal on Teen Pregnancy May Be Reduced by Sex Education in Schools, Says Study
  • Don on Prilosec, Nexium and Prevacid Tied to Higher Risk of Pneumonia
  • Meso on Brain Changes in Elderly Can Affect Mobility and Balance
  • About Us
  • Contact

Copyright © 2025 Mednews · Log in